Dihexa: Dosing Protocols
Dosing guidelines, reconstitution, and administration information
๐TL;DR
- โข1 dosing protocols documented
- โขReconstitution instructions included
- โขStorage: Store lyophilized powder at -20 degrees C. Protect from light and moisture. Reconstituted solutions should be stored at 2-8 degrees C and used promptly. Long-term stability data for reconstituted solutions have not been published.
Protocol Quick-Reference
Cognitive enhancement research
Dosing
Amount
2 mg/kg/day (preclinical oral dose in rats)
Frequency
Once daily (animal studies)
Duration
2-4 weeks (study-dependent)
Administration
Route
OralTiming
Oral administration in preclinical studies. Dihexa has approximately 38% oral bioavailability and crosses the blood-brain barrier.
Cycle
Duration
2-4 weeks (preclinical)
Repeatable
Single cycle
โ๏ธ Suggested Bloodwork (3 tests)
CBC with differential
When: Baseline
Why: Baseline blood cell counts
CMP (Comprehensive Metabolic Panel)
When: Baseline
Why: Liver and kidney function baseline
Tumor markers (if applicable)
When: Baseline
Why: Dihexa activates the c-Met/HGF pathway implicated in cell proliferation and cancer biology
๐ก Key Considerations
- โPreclinical only: no human clinical trials have been conducted
- โSafety concern: activates c-Met/HGF pathway involved in cancer progression
- โA key 2014 mechanistic study was retracted due to data fabrication
Unlock dosing protocols
Free access to research-backed dosing information for all peptides.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
| Purpose | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| Preclinical Cognitive Research (Animal Studies Only) | 2 mg/kg per day orally in aged rats (McCoy et al., 2013). No human dosing protocols have been established through clinical trials. | Once daily (oral administration in animal studies) | Study-dependent; typically 2-4 weeks in published research | All dosing information is derived from animal studies. No human clinical trials have been conducted. Human-equivalent doses cannot be reliably calculated from these data. |
Unlock full dosage protocols
Free access to complete dosing tables and protocol details.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
๐Reconstitution Instructions
As a research chemical, dihexa is typically supplied as a lyophilized powder. For research purposes, it is dissolved in DMSO for stock solutions or appropriate vehicle for animal studies. No standardized reconstitution protocol exists for human use.
๐งStorage Requirements
Store lyophilized powder at -20 degrees C. Protect from light and moisture. Reconstituted solutions should be stored at 2-8 degrees C and used promptly. Long-term stability data for reconstituted solutions have not been published.
Community Dosing Protocols
Compare these clinical doses with what 45+ community members report using.
Based on 45+ community reports
View community protocolsResearch Tools
Before You Begin
Review safety warnings and contraindications before starting any protocol.
Important Disclaimer#
Dihexa has not been evaluated in human clinical trials. No regulatory agency has approved it for any therapeutic use. All dosing information presented here is derived exclusively from published animal research and is provided for informational purposes only. Dihexa should not be used for self-medication.
Preclinical Dosing Data#
Animal Study Protocols#
The primary dosing data for dihexa comes from the McCoy et al. (2013) study, which evaluated oral dihexa in two rat models:
Aged Rat Model: 24-month-old Sprague-Dawley rats received dihexa at 2 mg/kg per day via oral gavage. This dose significantly improved spatial learning in the Morris water maze compared to vehicle-treated aged controls.
Scopolamine Model: Younger rats treated with scopolamine (a muscarinic antagonist that impairs memory formation) were given dihexa to assess its ability to reverse pharmacologically induced cognitive deficits. Dihexa reversed scopolamine-induced amnesia at similar dose ranges.
APP/PS1 Mouse Model: A 2021 study administered dihexa to APP/PS1 transgenic Alzheimer's model mice, demonstrating cognitive improvement and neuroprotective effects. Different dose levels were tested, though the oral route was used.
Route of Administration#
Dihexa is distinctive among cognitive peptides in being orally bioavailable (approximately 38% absorption). In preclinical research, it has been administered:
- Orally: The primary route in behavioral studies, taking advantage of the compound's oral bioavailability and BBB permeability
- Intracerebroventricular (ICV): Used in early mechanistic studies to confirm central activity
No Established Human Dosing#
There are no published human pharmacokinetic studies, dose-finding trials, or clinical protocols for dihexa. Any human dosing information encountered outside peer-reviewed literature should be treated as unverified and potentially unsafe. The translation of animal doses to human-equivalent doses requires species-specific pharmacokinetic data that does not exist for this compound.
Storage and Handling#
- Lyophilized powder: Store at -20 degrees C, protected from light and moisture
- Reconstituted solutions: Store at 2-8 degrees C; stability data for reconstituted preparations have not been published
- Solubility: Soluble in DMSO; limited aqueous solubility
Dosing Context#
Dihexa belongs to the Cognitive category of research peptides. Dosing protocols for Dihexa are derived from available clinical trial data. These protocols are provided for research reference only and do not constitute medical advice. Actual dosing decisions should be made by qualified healthcare providers based on individual patient factors.
Research Protocols#
The following dosing protocols have been documented in clinical research for Dihexa:
Preclinical Cognitive Research (Animal Studies Only)#
Dose: 2 mg/kg per day orally in aged rats (McCoy et al., 2013). No human dosing protocols have been established through clinical trials.
Frequency: Once daily (oral administration in animal studies)
Duration: Study-dependent; typically 2-4 weeks in published research
All dosing information is derived from animal studies. No human clinical trials have been conducted. Human-equivalent doses cannot be reliably calculated from these data.
Reconstitution and Preparation#
As a research chemical, dihexa is typically supplied as a lyophilized powder. For research purposes, it is dissolved in DMSO for stock solutions or appropriate vehicle for animal studies. No standardized reconstitution protocol exists for human use.
Storage Requirements#
Store lyophilized powder at -20 degrees C. Protect from light and moisture. Reconstituted solutions should be stored at 2-8 degrees C and used promptly. Long-term stability data for reconstituted solutions have not been published.
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Protocol updates
Get notified when we update dosing protocols or publish related comparisons.
Frequently Asked Questions About Dihexa
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.